Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma (ENSIGN)
ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma
Sponsor: Eric Bernicker, MD
Terminated
Lack of funding
Listed as NCT02831933, this PHASE2 trial focuses on Lung Squamous Cell Carcinoma Stage IV and Metastatic Uveal Melanoma and remains terminated or withdrawn. Sponsored by Eric Bernicker, MD, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Oct 2021 — Oct 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
May 2019 — Dec 2020 [monthly]
Recruiting PHASE2
-
Sep 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eric Bernicker, MD
For direct contact, visit the study record on ClinicalTrials.gov .